|1.||Meng, Tze-Chiang: 3 articles (09/2014 - 08/2007)|
|2.||Tyring, Stephen K: 3 articles (11/2004 - 04/2002)|
|3.||Rook, Alain H: 2 articles (09/2015 - 03/2014)|
|4.||Surber, Christian: 2 articles (09/2015 - 01/2013)|
|5.||Peine, Kevin J: 2 articles (01/2014 - 03/2013)|
|6.||Ainslie, Kristy M: 2 articles (01/2014 - 03/2013)|
|7.||Satoskar, Abhay R: 2 articles (01/2014 - 03/2013)|
|8.||Bachelder, Eric M: 2 articles (01/2014 - 03/2013)|
|9.||Gupta, Gaurav: 2 articles (01/2014 - 03/2013)|
|10.||Bardel, Emilie: 2 articles (07/2011 - 01/2011)|
09/01/2010 - "Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice."
11/01/2004 - "Resiquimod shows promise for other viral infections and as a vaccine adjuvant."
08/01/2007 - "Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies."
09/01/2014 - "Resiquimod increased trafficking of leukocytes, including B cells, CD4(+) and CD8(+) T cells, dendritic cells, macrophages, and granulocytes, in livers and spleens, which are the key target organs of visceralizing infection. "
09/01/2014 - "In addition, in mice with existing infections, therapeutic treatment with topical resiquimod led to significantly lower visceral parasite loads. "
|2.||Herpes Genitalis (Genital Herpes)
01/01/2013 - "Although effective against genital HSV-2 in animal models, development of topical resiquimod for the treatment of recurrent genital herpes in humans was stopped due to inconsistent results in clinical trials. "
11/01/2004 - "Resiquimod, the latest immune response modifier (IRM), has shown in vivo evidence of efficacy against herpes simplex virus (HSV) type 2. The first clinical trial involving resiquimod demonstrated that it reduced the recurrence rate of genital herpes, but phase III trials were suspended due to lack of efficacy. "
07/15/2001 - "In this study, 52 patients with frequently recurrent genital herpes applied topical resiquimod gel 0.01% (twice or thrice weekly) or 0.05% (once or twice weekly) or vehicle gel to herpes lesions for 3 weeks. "
02/01/2008 - "Application of resiquimod 0.01% two times per week for 3 weeks did not delay the healing of genital herpes lesions or reduce acute viral shedding."
02/01/2008 - "Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions."
04/01/2010 - "The efficacy of R-848 as an adjuvant for antibody therapy was tested using a CT26-HER2/neu solid tumor model. "
04/01/2010 - "In a mouse solid tumor model, R-848 treatment superadditively enhanced the effects of antitumor antibody. "
01/01/2014 - "These results show that resiquimod induces the differentiation of MDSCs into macrophages and dendritic cells, and also suggest that resiquimod may improve cancer immunotherapy by reducing immunosuppressive MDSCs."
01/01/2013 - "Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that are effective against viral and tumor lesions. "
08/01/2008 - "The imidazoquinoline compounds imiquimod and resiquimod are low-molecular-weight immune response modifiers that have potent anti-viral and anti-tumor properties. "
|4.||Asthma (Bronchial Asthma)
04/01/2011 - "Resiquimod, a TLR7/8 ligand, is protective against acute and chronic asthma, and it increases SLPI expression of macrophages in vitro. "
04/01/2011 - "Taken together, our study showed that the expression of SLPI protects against allergic asthma phenotypes, and treatment by resiquimod is independent of SLPI expression, displayed through the use of transgenic and knockout SLPI mice."
08/07/2009 - "The aim of the present study was to elucidate the molecular processes that were altered following resiquimod treatment and allergen challenge in a mouse model of allergic asthma. "
07/01/2011 - "We addressed the question whether the TLR7 ligand resiquimod (R848), which has been shown to be protective in several experimental allergic asthma protocols, can also suppress typical asthma symptoms once the disease is established. "
04/01/2011 - "To evaluate the role of SLPI in the development of asthma phenotypes and the effect of resiquimod treatment on SLPI, we assessed airway resistance and inflammatory parameters in the lungs of OVA-induced asthmatic SLPI transgenic and knockout mice and in mice treated with resiquimod. "
04/01/2011 - "Treatment of asthmatic transgenic mice with resiquimod increased the expression of SLPI and decreased inflammation in the lungs; resiquimod treatment was still effective in asthmatic SLPI knockout mice. "
01/01/2011 - "We show in this study that spleen cells activated by the TLR7 agonist resiquimod (R848) attenuate allergic inflammation upon adoptive transfer when they are recovered from wild-type, but not from iNKT cell-deficient Jα18(-/-) mice, which proves the specific involvement of this regulatory population. "
03/07/2008 - "Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice."
08/01/2004 - "These data indicate that R-848 effectively inhibits allergen-induced airway inflammation and hyper-reactivity by modulation of increased Th2-immune responses."
08/01/2004 - "Associated with the decrease in airway inflammation, single intranasal treatment with R-848 abolished the development of airway hyper-reactivity after allergen sensitization and airway challenges. "
|1.||R 848 (resiquimod)
|2.||Toll-Like Receptors (Toll-Like Receptor)
|6.||CpG ODN 2216
|7.||DNA (Deoxyribonucleic Acid)
|8.||Reactive Oxygen Species (Oxygen Radicals)